SCHEMBL10102652

SCHEMBL10102652

OCCCc1cc2cc(C(F)(F)F)ccc2nc1-c1ccc(F)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.43
KDM4E B2RXH2 1/20 0.38
DHFR P00374 3/20 0.38
TYMS P04818 2/20 0.38
TRPV1 Q8NER1 1/20 0.36
DHODH Q02127 2/20 0.35
BACE1 P56817 1/20 0.35
CTSK P43235 1/20 0.35
KCNH2 Q12809 1/20 0.35
TRPV3 Q8NET8 4/20 0.34
NAMPT P43490 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
ALOX5AP P20292 1/20 0.32
FEN1 P39748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005264 0.91 KDM4E (0.39) TRPA1KDM4EDHFRTYMSTRPV1
SCHEMBL13005263 0.88 DHFR (0.40) KDM4EDHFRTYMSTRPV1DHODH
SCHEMBL10107977 0.85 NPBWR1 (0.43) KDM4EDHFRTYMSTRPV1DHODH
SCHEMBL3383001 0.84 DHODH (0.45) KDM4EDHFRTYMSDHODHCTSK
SCHEMBL10102653 0.82 CTSK (0.40) KDM4EDHFRTYMSTRPV1DHODH
SCHEMBL10102644 0.81 GPBAR1 (0.42) KDM4EBACE1CTSKKCNH2
SCHEMBL10102657 0.81 NPBWR1 (0.44) KDM4ETRPV1DHODHBACE1CTSK
SCHEMBL10102646 0.79 CTSK (0.47) TRPA1CTSKKCNH2NAMPT
SCHEMBL10102671 0.77 DHODH (0.46) KDM4EDHFRTYMSDHODHBACE1
SCHEMBL10107982 0.75 KDM4E (0.36) KDM4EDHODHBACE1CTSKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B TRPA1 4742/4885KDM4E 2071/4885DHFR 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.